MediciNova,Inc. Logo

MediciNova,Inc.

Developing small-molecule drugs for neurology, respiratory, and liver diseases.

4875 | T

Overview

Corporate Details

ISIN(s):
US58468P2065
LEI:
Country:
Japan
Address:
米国カリフォルニア州ラ・ホイヤ、スウィート300、エグゼクティブ・スクエア4275
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for serious diseases with unmet medical needs. The company's primary development efforts are concentrated on neurology, respiratory, and liver diseases. Its pipeline includes candidates such as MN-221, targeting respiratory conditions like acute exacerbations of asthma and COPD, and MN-001 for fibrotic diseases, including liver fibrosis (NASH) and idiopathic pulmonary fibrosis (IPF).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 07:44
Registration Form
確認書
Japanese 8.4 KB
2025-09-12 07:43
Interim Report
半期報告書
Japanese 386.0 KB
2025-06-25 03:32
Regulatory News Service
臨時報告書
Japanese 16.6 KB
2025-06-10 06:52
Audit Report / Information
内部統制報告書
Japanese 51.3 KB
2025-06-10 06:51
Registration Form
確認書
Japanese 12.9 KB
2025-06-10 06:50
Annual Report
有価証券報告書
Japanese 3.0 MB
2024-09-11 04:32
Registration Form
確認書
Japanese 13.0 KB
2024-09-11 04:28
Interim Report
半期報告書
Japanese 436.9 KB
2024-06-17 09:06
Post-Annual General Meeting Information
臨時報告書
Japanese 15.4 KB
2024-06-13 05:03
Registration Form
確認書
Japanese 13.1 KB
2024-06-13 05:02
Quarterly Report
四半期報告書
Japanese 424.9 KB
2024-06-10 09:48
Audit Report / Information
内部統制報告書
Japanese 51.4 KB
2024-06-10 09:46
Audit Report / Information
有価証券報告書
Japanese 3.3 MB
2024-06-10 09:46
Registration Form
確認書
Japanese 12.9 KB
2023-12-12 06:01
Registration Form
確認書
Japanese 13.1 KB

Automate Your Workflow. Get a real-time feed of all MediciNova,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MediciNova,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MediciNova,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan
4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden
KLAR
Klotho Neurosciences, Inc. Logo
Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.
United States of America
KLTO
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan
9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan
4967
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America
KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan
177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea
102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America
950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea
041960

Talk to a Data Expert

Have a question? We'll get back to you promptly.